CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TG Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TG Therapeutics Inc
3020 Carrington Mill Blvd., Suite 475
Phone: (302) 658-7581p:302 658-7581 MORRISVILLE, NC  27560-5435  United States Ticker: TGTXTGTX
Business Summary
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Michael S.Weiss 59 6/16/2021 12/29/2011
Chief Financial Officer, Treasurer, Corporate Secretary Sean A.Power 43 12/29/2011 12/29/2011
Lead Independent Director Laurence N.Charney 78 6/16/2021 4/1/2012
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Ariston Pharmaceuticals, Inc.
TG Biologics, Inc.
TG Cell Therapy, Inc.
TG Therapeutics AUS Pty Ltd
TGTX

General Information
Number of Employees: 399 (As of 2/20/2026)
Outstanding Shares: 159,688,256 (As of 2/25/2026)
Shareholders: 196
Stock Exchange: NASD
Federal Tax Id: 363898269
Fax Number: (212) 554-4531


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 31, 2026